CG Oncology
Developing cretostimogene for bladder cancer alongside contract fill-and-finish manufacturing.
Something off on this page? Send us feedback.
Profile
Develops intravesical cretostimogene for high-risk and intermediate-risk non-muscle invasive bladder cancer, while controlled subsidiary Biovire earns contract fill-and-finish manufacturing revenue. No drug is approved or sold, leaving the business dependent on its sole candidate's clinical, regulatory, manufacturing, and commercialization path.
Develops cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy designed to destroy tumor cells directly and activate an immune response. The sole drug candidate targets bladder cancer through BOND-003 in high-risk BCG-unresponsive non-muscle invasive disease and PIVOT-006 in intermediate-risk disease.
Extends the program through CORE-008 monotherapy and combination cohorts across high-risk settings, alongside a North American expanded-access pathway. Completed late-stage trial enrollment, published BOND-003 results, and initiated a rolling U.S. biologics license application for the initial high-risk indication.
Generates commercial revenue through controlled subsidiary Biovire, which provides fill-and-finish manufacturing services and produces cretostimogene clinical supply. No product is approved or sold; clinical progress, regulatory approval, and commercialization depend on the sole candidate, while clinical trials and parts of manufacturing and distribution still rely on third parties.
Company facts
Key statistics
Year to date +77.9% · Average volume (30d) 765.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | $82 | $85 | |
| Jul 29, 2026 | H.C. Wainwright | Reiterate | Buy | $75 | $100 |
| May 14, 2026 | Truist Financial | Target | $75 | $82 | |
| May 11, 2026 | RBC Capital | Reiterate | Outperform | $79 | $81 |
| May 11, 2026 | Wedbush | Reiterate | Outperform | $70 | $80 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.66 | −$0.90 | −35.5% | $360.8K | $1.2M | +220.7% | +0.33% |
| Aug 6, 2026Q2 FY26 | −$0.66 | −$0.90 | −35.5% | $360.8K | $1.2M | +220.7% | +3.36% |
| May 8, 2026Q1 FY26 | −$0.58 | −$0.71 | −22.4% | $453.0K | $1.1M | +139.1% | −0.43% |
| Feb 27, 2026Q4 FY25 | −$0.61 | −$0.51 | +16.4% | $450.5K | $2.3M | +412.9% | −1.77% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $52.0K | $0 | $1.7M | $2.3M | $1.1M | $1.2M | |
| Gross profit | −$27.4M | −$31.3M | $89.0K | −$592.0K | −$1.9M | −$2.8M | |
| Operating income | −$42.2M | −$48.7M | −$51.1M | −$48.7M | −$66.4M | −$86.4M | |
| Net income | −$34.5M | −$41.4M | −$43.8M | −$41.3M | −$60.2M | −$79.1M | |
| Diluted EPS | −$0.45 | −$0.54 | −$0.57 | −$0.52 | −$0.71 | −$0.90 | |
| Gross margin | -52,721.2% | — | 5.3% | -25.5% | -173.5% | -239.2% | |
| Operating margin | -81,161.5% | — | -3,069.0% | -2,097.3% | -6,130.1% | -7,467.7% |
Fiscal years (4-quarter sums)FY23 $204.0K · FY24 $1.1M · FY25 $4.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.03B · Total debt $8.8M · Total assets $1.09B · Shareholders' equity $1.03B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 88.20M · Float 65.82M · 74.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 8.51M | 9.65% | 13F | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.62M | 7.50% | 13F | Aug 14, 2026 |
| Decheng Capital LLC | 6.37M | 7.22% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 6.26M | 7.09% | 13F | Aug 7, 2026 |
| Wellington Management Group LLP | 5.32M | 6.04% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Leonard E. Post | director | −1,000 | $74.54 |
| Jul 15, 2026 | Leonard E. Post | director | −1,000 | $71.17 |
| Jul 10, 2026 | James Mulay | director | −24,165 | $75.16 |
| Jun 25, 2026 | Brian Guan-Chyun Liu | director | +371,085 | $66.87 |
| Jun 24, 2026 | Leonard E. Post | director | −5,000 | $70.00 |
Peers
- ImmunityBio
Approved intravesical IL-15 immunotherapy plus BCG in NMIBC
- Johnson & Johnson
Late-stage intravesical gemcitabine system for high-risk NMIBC
- Merck
Approved checkpoint therapy in BCG-unresponsive high-risk NMIBC
- UroGen Pharma
Approved intravesical mitomycin therapy in recurrent LG-IR NMIBC
- enGene Therapeutics
Pivotal intravesical gene-therapy program for high-risk NMIBC
- Pfizer
Phase 3 PD-1 plus BCG program in BCG-naive high-risk NMIBC
- Protara Therapeutics
Intravesical cell-based immunotherapy in BCG-unresponsive NMIBC
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CG Oncology | $73.91 | −0.57% | $6.56B | — | — | 1,052.8 | — |
| ImmunityBio | $8.07 | +0.25% | $8.43B | — | — | 50.9 | +93.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| UroGen Pharma | $43.62 | −0.02% | $2.13B | — | 35.5 | 11.3 | +199.2% |
| enGene Therapeutics | $1.83 | +0.08% | $122.3M | — | — | — | — |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Protara Therapeutics | $3.82 | +0.26% | $214.7M | — | — | — | — |
| Median | 36.9 | 19.8 | 6.6 | +6.6% |